RPH-104 (Гофликицепт, Арцерикс®)
Проводит ООО «Р-Фарм Интернешнл»
Страница компанииОдноцентровое, рандомизированное, когортное, простое слепое сравнительное клиническое исследование c целью оценки фармакокинетики, безопасности и иммуногенности препарата RPH-104 при применении в новой дозировке 80 мг/мл и дозах 80 мг, 160 мг и 320 мг при однократном подкожном и внутривенном введении здоровым добровольцам
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/505/2024-10-28/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного.
- В исследовании участвуют здоровые добровольцы.
- Исследование идёт.
- Возраст участников: 18–45 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 220 чел. в стране «Россия».
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 12.2027.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Индекс массы тела18,5–29,9 кг/м²
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 18 · невключение: 14
Критерии включения
- Volunteers had to meet all the following inclusion criteria:
- Signed and dated Informed Consent Form in duplicate
- Males and females aged 18-45 years inclusive
- Body mass index:
- Cohorts A and B: normal range (18.5-29.9 kg/m²)
- Cohort C: normal range (18.5-29.9 kg/m²), body mass ≥55 and ≤100 kg
- Verified "healthy" diagnosis per standard clinical, laboratory, and instrumental examinations:
- Normal results for complete blood count, blood chemistry, coagulation tests, urinalysis, and ECG per center standards (screening tests performed ≤7 days before enrollment)
- Normal vital signs: SBP 90-129 mmHg, DBP 60-85 mmHg, pulse 60-100 bpm, body temperature 36.1-37.0℃, respiratory rate 12-20 breaths/min
- No tuberculosis (active, latent, or history) or other chronic infections/inflammatory diseases
- Satisfactory health status (per volunteer's opinion) for 30 days prior to consent
- "Normal" result for physical examination by investigator's judgment at screening
- Agreement to abstain from alcohol for 72 hours pre-dose until final PK blood sampling
- Willingness to comply with protocol procedures per investigator's judgment
- Agreement (by volunteers and their partners of reproductive potential for male volunteers) to abstain from heterosexual intercourse or use highly effective contraception from consent until 3 months post-goflikicept administration
- For female volunteers: willingness to consent to pregnancy outcome data collection and provide obstetric/pediatric clinic contacts if pregnancy occurs post-dosing
- Subjects were withdrawn from further participation in the study in the following cases:
- Detection, after inclusion of the subject in the study, of non-compliance with the inclusion criteria or presence, at the time of inclusion, of compliance with the
Критерии невключения
- (as decided by LLC "R-Pharm International", including retrospective analysis of information entered into the eCRF database)
- If the subject withdraws their consent to participate in the study
- If AEs or SAEs, laboratory abnormalities, or concomitant diseases are identified in the subject, which, in the opinion of the investigator or the Sponsor, make continued participation impossible or dangerous, or not in the best interest of the subject's welfare and safety
- In case of subject non-compliance (in this case, exclusion of the subject must be agreed upon with representatives of LLC "R-Pharm International", see Section 6.3 of the Clinical Study Protocol), or in the case of systematic major deviations in the timing of scheduled visits (more than 3 deviations from scheduled visit dates). For Cohort C: in case of missing any of Visits 09, missing two consecutive Visits 1015, or missing any 3 visits during the study
- If the study is terminated by decision of LLC "R-Pharm International", local ethics committees, or regulatory authorities
- In case of use of drugs prohibited by the Protocol
- If restrictions for study subjects are violated (in this case, exclusion of the subject must be agreed upon with representatives of LLC "R-Pharm International", see Section 6.2.3 of the Clinical Study Protocol "Other restrictions for study subjects")
- If there is suspicion of concurrent participation in another clinical study, including indirect laboratory evidence
- If the result of a test for alcohol, narcotic, or psychotropic substances is positive before administration of the study drug
- If SARS-CoV-2 is detected via PCR test or rapid antigen test prior to administration of the study drug
- If other reasons arise during the study that prevent the study from being conducted according to the protocol
- In the event of the subject's death
- For female subjects a positive pregnancy test (test strip), performed at the center prior to administration of the study drug
- In case of missed blood sample collections (applicable only for Cohort C)
Источник: ClinicalTrials.gov, NCT07206043 · запись обновлена в реестре 3 октября 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 6
- The area under the plasma drug concentration-time curve (AUC) of RPH-104 from the moment of administration to infinity after a single injection of RPH-104 — Up to day 61 ± 3
- The maximum concentration of RPH-104 in the blood serum after a single injection of RPH-104 — Up to day 61 ± 3
- Percentage of volunteers (%) with AEs and SAEs — Up to day 61 ± 3
- Percentage of volunteers (%) with AEs ≥ Grade 3 according to CTCAE 5.0 — Up to day 61 ± 3
- Percentage of volunteers (%) with ADRs and serious ADRs — Up to day 61 ± 3
- Percentage of volunteers (%) with ADRs ≥ Grade 3 according to CTCAE 5.0 — Up to day 61 ± 3
- Percentage of volunteers (%), who prematurely discontinued participation in the study due to AE/SAE and ADR/serious ADR — Up to day 61 ± 3
- Percentage of volunteers (%) with AEs of special interest — Up to day 61 ± 3
- Percentage of volunteers (%), who developed binding antibodies to RPH-104 — Up to day 61 ± 3
- Percentage of volunteers (%), who developed neutralizing antibodies to RPH-104 — Up to day 61 ± 3
Цель исследования
The purpose of this study is to evaluate the safety, immunogenicity and pharmacokinetics of RPH-104 after single intravenous and subcutaneous administration to healthy volunteers at different doses
Области и заболевания
Где проходит
1 центр в 1 городеОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 505 от 28.10.2024 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07206043 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.